According to the Complaint, Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on transforming migraine treatment through the discovery, development, and commercialization of novel therapeutic antibodies.

This action stems from a proposed transaction announced on September 16, 2019, pursuant to which Alder BioPharmaceuticals, Inc. will be acquired by H. Lundbeck A/S.

On September 16, 2019, Alder’s Board of Directors caused the Company to enter into an agreement and plan of merger with Lundbeck.

On September 23, 2019, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.

This case was voluntarily dismissed on January 10, 2020.